Abstract
Staar Surgical will report its fiscal second-quarter results on August 12, 2026 Post-Mkt; this preview compiles consensus forecasts, the company’s latest preannouncement, last quarter’s performance, and key drivers that could shape the print and outlook.
Market Forecast
Consensus expects Staar Surgical’s current-quarter revenue to be 90.57 million US dollars, up 125.63% year over year, with adjusted EPS estimated at 0.16 US dollars, up 123.60% year over year; the EBIT estimate stands at 8.11 million US dollars, up 123.63% year over year. The company has already preannounced preliminary net sales “over 90.00 million US dollars” for the quarter, which is broadly aligned with the market’s revenue estimate and indicates at least a doubling year over year.
The core sales engine—the non-consignment channel—remains the dominant contributor and should benefit from continued procedure normalization and stable pricing, while distribution remains a smaller portion of the mix. The most promising growth vector is the China-related EVO ICL procedure recovery; while the company did not break out regional sales in the preannouncement, its “over 90.00 million US dollars” preliminary net sales imply at least 103.30% year-over-year growth from 44.30 million US dollars a year ago, signaling sustained momentum into this quarter.
Last Quarter Review
In the prior quarter, Staar Surgical reported revenue of 93.52 million US dollars, up 119.59% year over year, with a gross profit margin of 73.63%, GAAP net profit attributable to the parent company of 5.21 million US dollars, a net profit margin of 5.57%, and adjusted EPS of 0.23 US dollars, up 143.40% year over year. A notable highlight was the across-the-board beat versus consensus on both revenue (93.52 million US dollars vs. 75.51 million US dollars) and EPS (0.23 US dollars vs. a negative estimate), reflecting operating leverage as volumes recovered.
On business mix, non-consignment sales contributed 75.49 million US dollars and the distribution channel contributed 18.03 million US dollars, while overall company revenue grew 119.59% year over year; mix supported the high gross margin profile and positive earnings inflection.
Current Quarter Outlook
Main business momentum: Non-consignment channel and procedure volumes
The non-consignment channel remains the backbone of the revenue model and is positioned to carry the bulk of the quarter’s reported sales. The company’s preliminary disclosure of “over 90.00 million US dollars” in net sales, closely tracking the 90.57 million US dollars consensus, implies that procedure volumes stayed healthy after the strong prior quarter. Pricing appears stable and aligned with a premium mix that helped deliver a 73.63% gross margin last quarter; if volumes remain elevated, management could deliver sequential operating leverage through better absorption and sales efficiency. Volume cadence remains the most important operational signal for the quarter: stable day-to-day procedure activity in key geographies and a balanced channel inventory position would support both top-line delivery and margin resilience. Given the prior quarter’s high conversion of revenue to profitability, investors will calibrate results to see if the company can hold a gross margin corridor near last quarter’s level while supporting opex investments tied to commercial execution.
Most promising business: China-driven EVO ICL recovery
Management and subsequent media updates pointed to a demand recovery in China after last year’s distributor destocking, which has been a major swing factor for year-over-year comparisons. The second-quarter preliminary update—“over 90.00 million US dollars” versus 44.30 million US dollars in the year-ago quarter—signals at least 103.30% year-over-year growth and suggests that China-linked procedure activity helped anchor the step-up. While the company has not provided a standalone revenue figure for China, the directionally strong rebound implies better utilization across clinics and continued interest in premium refractive solutions. For this quarter, the pacing of appointment conversions, surgeon scheduling, and any residual channel normalization are the levers to watch; incremental visibility into order linearity and intra-quarter sell-through would help investors handicap the sustainability of growth heading into the second half.
Stock-price drivers this quarter: Guidance quality, margin trajectory, and channel health
Three elements are likely to set the stock’s direction around the print. First, guidance quality and specificity: investors will look for whether management provides explicit revenue and profitability commentary for the next quarter or the full year, and whether it contextualizes geopolitical and macro headwinds observed in certain EMEA and Asia-Pacific markets. Second, margin trajectory: last quarter’s 73.63% gross margin and a return to profitability established a higher earnings baseline; the market will parse gross margin puts and takes including product mix, geographic mix, and manufacturing absorption, as well as any temporary cost pressures. Third, channel health and order linearity: signs that distributor inventory is aligned with underlying consumption, with minimal end-of-quarter pull-ins, would underpin confidence in demand quality; conversely, any reacceleration in inventory build could temper enthusiasm even if headline revenue meets expectations.
Revenue and EPS bridge: Quantifying what needs to happen
To land near the 90.57 million US dollars revenue estimate, current trends suggest that the company needs to sustain the volume levels implied by its preannouncement across its two commercial channels, with a mix balance similar to last quarter’s 75.49 million US dollars non-consignment versus 18.03 million US dollars distribution. On earnings, the consensus adjusted EPS estimate of 0.16 US dollars, up 123.60% year over year, implies mid- to high-70% gross margins and disciplined operating expense growth relative to revenue. Given an EBIT estimate of 8.11 million US dollars, up 123.63% year over year, the operating model is expected to demonstrate leverage even if opex remains elevated to support surgeon training and commercial initiatives; the cadence of opex investment versus revenue should be a focal point on the call.
Gross margin watch points: Mix, absorption, and pricing discipline
Last quarter’s gross margin of 73.63% established a constructive reference point. Into this quarter, three variables stand out: product and geographic mix, plant absorption, and pricing. If the quarter’s sales are led by premium lenses associated with higher average selling prices, and mix remains tilted toward non-consignment, margin retention becomes more likely. Sustained volume at or above the preannounced level supports absorption and spreads fixed costs across a larger revenue base, which historically helps offset currency or logistics noise. Pricing discipline is the third leg, and nothing in the latest updates points to abrupt changes; continuity here would complement volume-led margin stability.
Cash and profitability signals: Net margin path and EBIT conversion
With a last-quarter net profit margin of 5.57% and EBIT of 7.98 million US dollars, the company reestablished profitability after a period of volatility. For the current quarter, the EBIT estimate of 8.11 million US dollars implies that management can hold, if not modestly expand, operating income on a broadly similar revenue base to last quarter. Conversion from gross profit to EBIT depends on marketing cadence, training investments, and support costs across regions that have faced macro or geopolitical constraints; clarity on these items will frame expectations for the second half. Investors will also be looking for commentary on working capital discipline—particularly receivables duration and any inventory adjustments—as these determine how earnings translate into cash generation.
Regional currents: Americas consistency versus EMEA and selective APAC headwinds
Updates after the prior quarter highlighted double-digit percentage growth in the Americas and resilience in core demand trends. The company also acknowledged headwinds in parts of EMEA and Asia-Pacific tied to geopolitics and macro. For the quarter at hand, the relative balance between Americas momentum and selective international pressure will likely influence both revenue and mix. Confirmation that the Americas maintained double-digit percentage growth would help offset any softness elsewhere and could modestly enhance gross margin, contingent on product mix. Any commentary detailing improvement or stabilization in affected regions will serve as a positive read-through for the second half.
What the preannouncement implies for the print
The preannouncement of “over 90.00 million US dollars” effectively narrowed the revenue outcome range and provides investors with a firmer base case for the quarter. Relative to consensus at 90.57 million US dollars, the result will likely hinge on whether reported revenue rounds modestly above or below that mark and on the quality of the accompanying margin and guidance commentary. Because the prior quarter already demonstrated improved operating leverage, the incremental surprise potential resides less in the top line and more in gross margin durability and the shape of second-half guidance.
Key variables to monitor on the call
Management’s discussion of channel inventories and sell-through versus sell-in will be integral to assessing the durability of growth beyond this quarter. Any updates on training capacity and uptake, as well as operating days and procedure utilization patterns, will help investors triangulate near-term demand. Finally, updated views on macro and geopolitical exposures in specific markets—particularly any changes versus last quarter’s framing—will influence how the market discounts the trajectory into the remainder of the year.
Analyst Opinions
Across recent analyst and institutional commentary this year, the ratio of bullish to bearish views leans positive—by our count, approximately 75% bullish versus 25% bearish—so we present the majority perspective. The bullish camp emphasizes that the company’s two-quarter trajectory of stronger sales and operating leverage suggests it is either at or near an inflection in earnings quality. Wedbush shifted to an Outperform rating and lifted its price target to 40 US dollars following the May results, citing improving execution and confidence that the sales recovery is translating into sustainable profitability. That upgrade was accompanied by incremental positive actions from other institutions that raised target prices after the company exceeded first-quarter expectations, reinforcing a constructive stance into the second quarter.
Supportive analysts point to three pillars for the upcoming print. First, the alignment between the “over 90.00 million US dollars” preannouncement and the 90.57 million US dollars consensus reduces top-line uncertainty and reframes investor attention toward profitability and guidance. Second, the last quarter’s 73.63% gross margin and positive net income demonstrate that the operating framework can convert volume into bottom-line results, especially if the quarter’s product mix remains favorable. Third, commentary indicating robust demand in the Americas and a recovery in China-focused procedures provides a tangible path for sequential stability despite acknowledged headwinds in certain EMEA and Asia-Pacific locales.
The bullish thesis also underscores what would validate further upside beyond the event. Analysts want to see continuity in gross margin near last quarter’s level, evidence of disciplined operating expense growth relative to revenue, and proof that channel inventories remain healthy. They also look for refined guidance that brackets second-half expectations in a way that acknowledges macro variability while preserving the improved earnings trajectory. If reported results track the preannouncement and management offers a constructive, transparent framework for the back half, the majority view anticipates that consensus models could trend higher on both revenue and EPS, anchoring a more durable re-rating of the shares.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments